Collegium Pharmaceutical, Inc.
NASDAQ:COLLDrug Manufacturers - Specialty & Generic
-$0.24 today
- Market cap
- $805.79M
- Beta
- 0.75
- P/E (TTM)
- 14.3
- EPS (TTM)
- $2.34
Volume 0.49M
Average 0.50M
COLL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Collegium Pharmaceutical, Inc.NASDAQ: COLL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $14.5M rose 499.8% year over year, ahead of the +70.7% change in trailing-twelve-month net income. Sequentially, it fell 14.5% from the prior quarter.
Context
- Net income amounted to 8.1% of revenue in FY2025, down 2.9 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $297.16M (+372.7%) for the fiscal year ending Dec 2026, a step up from the -9.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.5M-14.5% QoQ
- Last fiscal yearDec 2025
- $62.87M-9.1% YoY
- LTMMar 2026
- $74.95M+70.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +499.8% | +461.1% | -38.7 pp |
| 1 year | -9.1% | +372.7% | +381.8 pp |
| 3-year CAGR | — | +58.9% | — |
| 5-year CAGR | +48.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 62.87M USD
- Year-over-year change
- -9.1%
- 4-year CAGR
- -3.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.87M | -9.1% |
| FY2024 | 2024-12-31 | 69.19M | +43.7% |
| FY2023 | 2023-12-31 | 48.16M | +292.6% |
| FY2022 | 2022-12-31 | (25M) | -135.0% |
| FY2021 | 2021-12-31 | 71.52M | — |
Net Income vs competitors
How COLL compares with its peers on the latest reported figures
- COLL's LTM Mar 2026 net income of $74.95M is the 2nd largest of the 3 companies compared; the peer median is $187.75M.
- Its year-over-year change of +70.7% is the lowest of 3, against a peer median of +257.9%.
- Net income amounts to 9.4% of revenue for COLL, versus a peer median of 562.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $380.63M | +410.8% | +148.5% | 1124.1% | |
| LTM Mar 2026 | $74.95M | +70.7% | — | 9.4% | |
| LTM Mar 2026 | $5.14M | +105.0% | -23.8% | 0.7% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding COLL) | $187.75M | +257.9% | +62.4% | 562.4% | |
Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 71.52M | (25M) | 48.16M | 69.19M | 62.87M |
| Depreciation & Amortization | 68.92M | 138.94M | 149.26M | 169.16M | 220.82M |
| Deferred Income Tax | (78.04M) | (8.39M) | (2.15M) | (26.81M) | (25.66M) |
| Stock-Based Compensation | 24.26M | 22.87M | 27.14M | 32.4M | 41.91M |
| Change in Working Capital | 13.49M | (12.71M) | 21.73M | (54.98M) | 3.76M |
| Accounts Receivables | (22.52M) | (21.78M) | 3.59M | (4.41M) | 17.2M |
| Inventory | (2.3M) | 48.27M | 14.17M | 13.93M | (5.35M) |
| Accounts Payables | (5.83M) | (707K) | 5.06M | (11.28M) | 6.72M |
| Other Working Capital | 44.13M | (38.5M) | (1.09M) | (53.21M) | (14.81M) |
| Other Non-Cash Items | 3.42M | 8.52M | 30.62M | 16.02M | 25.62M |
| Operating Cash Flow | 103.56M | 124.23M | 274.75M | 204.98M | 329.32M |
| Capital Expenditures | (1.94M) | (1.62M) | (461K) | (1.65M) | (1.74M) |
| Acquisitions (Net) | 0 | (572.07M) | 0 | (267.54M) | 0 |
| Purchases of Investments | 0 | 0 | (92.35M) | (111.17M) | (126.97M) |
| Sales of Investments | 0 | 0 | 22M | 92.6M | 65.18M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.94M) | (573.69M) | (70.81M) | (287.76M) | (63.53M) |
| Debt Repayment | (50M) | 442.68M | (65.92M) | 7.52M | (70.38M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 5.64M |
| Common Stock Repurchased | (47.86M) | (14.06M) | (75M) | (60.03M) | (25.1M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.56M | 8.1M | 740K | (8.1M) | (20.4M) |
| Financing Cash Flow | (89.3M) | 436.72M | (140.18M) | (60.6M) | (110.25M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 12.31M | (12.74M) | 63.76M | (143.38M) | 155.55M |
| Free Cash Flow | 101.61M | 122.61M | 274.29M | 203.33M | 327.58M |
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
Intrinsic Alpha fair value
Locked
Current Price
$25.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.